ArticleClinical case reports2021
Thyroid angiosarcoma (TAS) - A rare diagnosis not to be missed.
Article in Clinical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Recurrent idiopathic esophageal perforation complicated by thyroid abscess: a case report and review of the literature.AME case reports · 2026Article
- Thyroid angiosarcoma: a rare malignancy - case report and systematic review of the literature.Thyroid research · 2025Review
- Unusual Presentation of Papillary Thyroid Carcinoma as a Lateral Neck Cystic Mass: A Case Report.Cureus · 2024Article
- The effect of thyroid cancer on the survival of patients with digestive system tumors using SEER database.Scientific reports · 2024Article
- Phthalate and gallstones: the mediation of insulin.Frontiers in public health · 2024Article
- Neck Surgery for Non-Well Differentiated Thyroid Malignancies: Variations in Strategy According to Histopathology.Cancers · 2023Review
- Non-alpine primary thyroid angiosarcoma.Archives of endocrinology and metabolism · 2022Article
- Thyroid angiosarcoma (TAS) - A rare diagnosis not to be missed.Clinical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raising awareness about primary TAS, a rare and aggressive mesenchymal tumor, is important so that early diagnosis and undelayed radical surgery along with complementary radiation are possible. Extending the existing knowledge on the course and final outcome of the disease may help identify the best treatment approach to improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.